Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researchers aim to speed drug discovery with human-understandable ML models

By Brian Buntz | November 18, 2020

FlowchartResearchers at Purdue University have devised chemical reactivity flowcharts and novel machine learning models that could accelerate drug discovery.

Although the use of machine learning for drug development has grown, researchers’ ability to understand machine learning recommendations has been limited.

In a paper published in Organic Letters, Purdue professor Gaurav Chopra noted that the machine learning (ML) models involved in the research were “human understandable.” The models could potentially boost chemists’ capability of interpreting chemical reaction outcomes related to organic and process chemistry.

“The ML research presented here can be used today within pharma to develop their discovery, process chemistry and developmental pipelines and enhance efficiency,” Chopra said.

The machine learning models rely on chemical reactivity flowcharts trained on a small number of chemical reactions. “Of course, more data helps, but the statistically robust machine learning models we developed help with less data, which I think will help pharma readily integrate this in their pipelines with minimal cost compared to developing large programs for infrastructure,” Chopra said. “We experimentally tested our models with less data including testing the new experiment that was based on the chemical reactivity flowchart.”

The researchers hope the machine learning models will improve drug developers’ ability to interpret chemical reactivity — especially related to N-Sulfinyl imines, a class of chemical compounds containing double bonds of carbon and nitrogen.

The Purdue researchers chose N-Sulfinyl imines owing to their widespread use for various chemical transitions in organic chemistry.

Machine learning models have traditionally required experimental training datasets requiring considerable manual experimentation.

The Purdue researchers assert that it is possible to train machine learning models using relatively small but targeted datasets.

To test their research, they used a fast multi-component reaction of acyclic or cyclic N-sulfonyl imines, which they used to predict reaction outcomes.

The researchers used density-functional theory to explain what they termed the “fast and peculiar reactivity mechanism of N-Sulfinyl imines to shed light on the compounds’ transition states and intermediates.

To explain the machine model’s prediction of reaction outcomes, the researchers developed a chemical reactivity flowchart.

The researchers state that the machine learning approach can serve as a basis for any multi-component reaction or chemical reaction to synthesize a library of chemical compounds.

“I think that the chemical reactivity flowcharts will help chemists not follow dead-end leads and suggest new experiments to do for the particular reaction of their interest during drug development,” Chopra concluded. “The major point here is that you don’t need large-scale data and these models can be used readily for day-to-day chemistry or reaction discovery or development versus using large-scale robotics.”


Filed Under: Drug Discovery
Tagged With: AI, artificial intelligence, cyclic N-sulfonyl imines, machine learning, Machine learning models, Purdue University
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE